Literature DB >> 33968476

Breakthrough Seizure Associated With Kratom Use in Patients With Epilepsy.

Devin J Burke1, Sarah G Mahonski1, Anne C Van Cott1.   

Abstract

PURPOSE OF REVIEW: Kratom (mitragynine) is a commercially available herbal supplement that is gaining popularity in the United States. Kratom is associated with a variety of neurologic effects. This review will discuss kratom's association with seizure through 3 cases and highlight what neurologists should know about kratom's clinical effects and legal status. RECENT
FINDINGS: Kratom is currently commercially available, unscheduled by the US Drug Enforcement Administration, and a topic of regulatory debate in the United States. Large poison center reviews have suggested that kratom use is associated with seizure. There have been limited case studies to corroborate this finding. We present 3 cases in which seizures were associated with kratom use in patients treated for epilepsy.
SUMMARY: Since 2008, kratom use is rising in prevalence in the United States aided by lack of regulation. Neurologists need to be aware of its association with seizure and other neurologic side effects.
© 2020 American Academy of Neurology.

Entities:  

Year:  2021        PMID: 33968476      PMCID: PMC8101317          DOI: 10.1212/CPJ.0000000000000846

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  25 in total

1.  Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton.

Authors:  Robert Kronstrand; Markus Roman; Gunilla Thelander; Anders Eriksson
Journal:  J Anal Toxicol       Date:  2011-05       Impact factor: 3.367

2.  Patterns of Kratom use and health impact in the US-Results from an online survey.

Authors:  Oliver Grundmann
Journal:  Drug Alcohol Depend       Date:  2017-05-10       Impact factor: 4.492

3.  Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.

Authors:  András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  J Med Chem       Date:  2016-09-02       Impact factor: 7.446

4.  Kratom exposures reported to United States poison control centers: 2011-2017.

Authors:  Sara Post; Henry A Spiller; Thitphalak Chounthirath; Gary A Smith
Journal:  Clin Toxicol (Phila)       Date:  2019-02-20       Impact factor: 4.467

5.  Deaths in Colorado Attributed to Kratom.

Authors:  Ken Gershman; Krista Timm; Meredith Frank; Laurissa Lampi; Jonathan Melamed; Roy Gerona; Andrew A Monte
Journal:  N Engl J Med       Date:  2019-01-03       Impact factor: 91.245

6.  Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers - United States, 2010-2015.

Authors:  Mehruba Anwar; Royal Law; Josh Schier
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-07-29       Impact factor: 17.586

Review 7.  Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.

Authors:  Walter C Prozialeck; Jateen K Jivan; Shridhar V Andurkar
Journal:  J Am Osteopath Assoc       Date:  2012-12

Review 8.  Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom.

Authors:  Dimy Fluyau; Neelambika Revadigar
Journal:  Front Psychiatry       Date:  2017-04-24       Impact factor: 4.157

Review 9.  The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.

Authors:  Jack E Henningfield; Reginald V Fant; Daniel W Wang
Journal:  Psychopharmacology (Berl)       Date:  2017-12-23       Impact factor: 4.530

10.  Kratom policy: The challenge of balancing therapeutic potential with public safety.

Authors:  Walter C Prozialeck; Bonnie A Avery; Edward W Boyer; Oliver Grundmann; Jack E Henningfield; Andrew C Kruegel; Lance R McMahon; Christopher R McCurdy; Marc T Swogger; Charles A Veltri; Darshan Singh
Journal:  Int J Drug Policy       Date:  2019-05-16
View more
  1 in total

1.  Acute, Sublethal, and Developmental Toxicity of Kratom (Mitragyna speciosa Korth.) Leaf Preparations on Caenorhabditis elegans as an Invertebrate Model for Human Exposure.

Authors:  Samantha Hughes; David van de Klashorst; Charles A Veltri; Oliver Grundmann
Journal:  Int J Environ Res Public Health       Date:  2022-05-22       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.